CL2023003443A1 - Método acelerado para elaborar formulaciones de proteínas liofilizadas - Google Patents
Método acelerado para elaborar formulaciones de proteínas liofilizadasInfo
- Publication number
- CL2023003443A1 CL2023003443A1 CL2023003443A CL2023003443A CL2023003443A1 CL 2023003443 A1 CL2023003443 A1 CL 2023003443A1 CL 2023003443 A CL2023003443 A CL 2023003443A CL 2023003443 A CL2023003443 A CL 2023003443A CL 2023003443 A1 CL2023003443 A1 CL 2023003443A1
- Authority
- CL
- Chile
- Prior art keywords
- protein formulations
- preparing lyophilized
- accelerated method
- lyophilized protein
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195265P | 2021-06-01 | 2021-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003443A1 true CL2023003443A1 (es) | 2024-06-14 |
Family
ID=82100125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003443A CL2023003443A1 (es) | 2021-06-01 | 2023-11-20 | Método acelerado para elaborar formulaciones de proteínas liofilizadas |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4553432T3 (da) | 2023-11-08 | 2026-06-29 | Bachem Holding Ag | Tørrepose og tørresystem |
| CN122122428A (zh) | 2023-11-08 | 2026-05-29 | 巴克姆股份公司 | 干燥袋和干燥系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| AU2001264946A1 (en) | 2000-05-24 | 2001-12-03 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| HUE059339T2 (hu) * | 2017-09-15 | 2022-11-28 | Amgen Inc | Eljárás terápiás fehérje liofilizált gyógyászati kiszerelésére |
| EP4200333A1 (en) * | 2020-08-24 | 2023-06-28 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
| IL299766A (en) * | 2020-09-14 | 2023-03-01 | Amgen Inc | Method of making lyophilized protein formulations |
-
2022
- 2022-06-01 IL IL307677A patent/IL307677A/en unknown
- 2022-06-01 KR KR1020237040273A patent/KR20240016260A/ko active Pending
- 2022-06-01 AR ARP220101446A patent/AR126044A1/es unknown
- 2022-06-01 AU AU2022285665A patent/AU2022285665A1/en active Pending
- 2022-06-01 CN CN202280030941.2A patent/CN117241787A/zh active Pending
- 2022-06-01 CA CA3217210A patent/CA3217210A1/en active Pending
- 2022-06-01 EP EP22731446.5A patent/EP4346778A1/en active Pending
- 2022-06-01 WO PCT/US2022/031694 patent/WO2022256359A1/en not_active Ceased
- 2022-06-01 TW TW111120372A patent/TW202313108A/zh unknown
- 2022-06-01 JP JP2023573384A patent/JP2024521329A/ja active Pending
- 2022-06-01 US US18/561,081 patent/US20240368254A1/en active Pending
- 2022-06-01 MX MX2023014034A patent/MX2023014034A/es unknown
- 2022-06-01 BR BR112023024757A patent/BR112023024757A2/pt unknown
-
2023
- 2023-11-20 CL CL2023003443A patent/CL2023003443A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024521329A (ja) | 2024-05-31 |
| AU2022285665A9 (en) | 2023-10-26 |
| TW202313108A (zh) | 2023-04-01 |
| EP4346778A1 (en) | 2024-04-10 |
| CN117241787A (zh) | 2023-12-15 |
| WO2022256359A1 (en) | 2022-12-08 |
| AR126044A1 (es) | 2023-09-06 |
| US20240368254A1 (en) | 2024-11-07 |
| KR20240016260A (ko) | 2024-02-06 |
| AU2022285665A1 (en) | 2023-10-19 |
| BR112023024757A2 (pt) | 2024-02-15 |
| CA3217210A1 (en) | 2022-12-08 |
| IL307677A (en) | 2023-12-01 |
| MX2023014034A (es) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
| WO2021097365A3 (en) | Antigen-binding proteins targeting shared neoantigens | |
| CL2023001092A1 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| CL2021002241A1 (es) | Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) | |
| CL2021002534A1 (es) | Métodos y composiciones para la inserción de secuencias codificantes de anticuerpos en un locus de puerto seguro. | |
| CL2021000458A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359) | |
| CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
| MX2024014691A (es) | Enlazadores de conjugacion mejorados | |
| UY38049A (es) | Anti-pd-1 anticuerpos y métodos de tratamiento | |
| MX2019000730A (es) | Proteinas multiespecificas de union al antigeno y metodos de uso de estas. | |
| MX2018013548A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
| BR112017013661A2 (pt) | conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
| MX2024009272A (es) | Constructos de anticuerpos de acidos nucleicos optimizados. | |
| MX2023006817A (es) | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. | |
| CO2023015915A2 (es) | Anticuerpos anti-ccr8 | |
| BR112016020009A2 (pt) | anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma | |
| MX2023013382A (es) | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. | |
| CL2017003273A1 (es) | Inmunoglobulinas conjugadas en cys80 | |
| CL2023002225A1 (es) | Proteínas de unión a psma y usos de estas. | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| CO2021005066A2 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
| CL2023000084A1 (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas | |
| BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
| AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso |